Ye, J., Hou, M., Ma, D., Gui, Y. (2026). Cadonilimab combined with anlotinib in patients with advanced NSCLC refractory to prior systemic therapy and anti–PD-(L)1 antibodies: A phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e20507